Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
J Manag Care Spec Pharm
; 28(6): 592-603, 2022 Jun.
Article
en En
| MEDLINE
| ID: mdl-35352995
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Diabetes Mellitus Tipo 2
/
Hipoglucemia
Tipo de estudio:
Health_economic_evaluation
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
J Manag Care Spec Pharm
Año:
2022
Tipo del documento:
Article
País de afiliación:
Nueva Caledonia